All In Biotech

Drug Trial Radar · NCT02172872

"InDACtion" vs "3+7" Induction in AML

10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Last checked: Nov 20, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

606

Actual

Start

Nov 28, 2014

Primary completion

Mar 7, 2022

Study completion Dec 2023

Sponsor

Sponsor type
Research network
Collaborators
Janssen Pharmaceuticals; Gruppo Italiano Malattie EMatologiche dell'Adulto
First posted
Jun 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the survival has not been improved during the last decades. The purpose of this study is to determine whether frontline therapy with a 10-day decitabine schedule provides a better survival than standard intensive combination chemotherapy in elderly AML patients (\>= 60 years).

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • standard combination chemotherapyDrug

    1. Cycle 1 1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days. 2. Cycle 2 1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days. 3. Cycle 3 (mini-ICE) 1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days 3. etoposide (100 mg/m²) infusion (1 hr) for 3 days 4. Cycle 4 (mini-ICE) (optional) 1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days 3. etoposide (100 mg/m²) infusion (1 hr) for 3 days

  • decitabineDrug

    1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days 2. Cycle 2 1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days 2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days 3. Cycle 3 1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days 2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days 4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days 5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: 4.9 years from first patient in

Locations

53 sites in 9 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Brussels, Belgium

  • C.H.U. Sart-Tilman

    Liège, Belgium

  • CHR De La Citadelle

    Liège, Belgium

  • UZ Antwerpen

    Edegem, Antwerpen, Belgium

  • UZ Brussel

    Jette, Brussels Capital, Belgium

  • CHR Verviers

    Verviers, Liège, Belgium

  • A.Z. St. Jan

    Bruges, West-Vlaanderen, Belgium

  • National Specialized Hospital for Active Treatment of Haematological Diseases

    Sofia, Bulgaria

  • Clinical Hospital Merkur

    Zagreb, Croatia

  • University Hospital Rebro

    Zagreb, Croatia

  • CHU de Caen - Hôpital Côte de Nacre

    Caen, France

  • CHU de Nantes - Hôtel Dieu

    Nantes, France

  • Assistance Publique - Hôpitaux de Paris - Hôpital Saint Antoine

    Paris, France

  • Universitätsklinikum Aachen AÖR - Medizinische Fakultät der RWTH

    Aachen, Germany

  • Klinikum Augsburg

    Augsburg, Germany

  • Helios Kliniken - Helios Klinikum Berlin-Buch

    Berlin, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitaetklinikum Halle - Martin Luther Universitaet - Universitaetsklinikum Halle (Saale)

    Halle, Germany

  • Klinikum Der Phillips - Universität Marburg

    Marburg, Germany

  • Universitaet Rostock - Medizinische Fakultaet

    Rostock, Germany

  • Universitaetsklinikum Tuebingen-Uni Kliniken Berg

    Tübingen, Germany

  • Azienda Ospedaliero Universitaria - Ospedali Riuniti

    Ancona, Italy

  • Universita Degli Studi Di Bari - Policlinico

    Bari, Italy

  • Universita di Bologna

    Bologna, Italy

  • Ospedale Regionale A. Pugliese

    Catanzaro, Italy

  • Ospedali Riuniti Foggia

    Foggia, Italy

  • Azienda Ospedaliero - Universitaria Policlinico di Modena

    Modena, Italy

  • Amedeo Avogadro University of Eastern Piedmont-Ospedale Maggiore della Carita

    Novara, Italy

  • La Maddalena S.P.A.

    Palermo, Italy

  • Ospedale San Salvatore

    Pesaro, Italy

  • AUSL Romagna - Ospedale Santa Maria dell Croci

    Ravenna, Italy

  • Arcispedale Di S. Maria Nuova

    Reggio Emilia, Italy

  • AUSL Romagna - Ospedale Infermi di Rimini

    Rimini, Italy

  • H. San Giovanni - Addolorata

    Roma, Italy

  • Universita Degli Studi Di Roma La Sapienza - Ospedale Sant'Andrea

    Roma, Italy

  • Azienda Ospedallera Universitaria - Policlinico Tor Vergata

    Rome, Italy

  • Instituto Regina Elena / Instituti Fisioterapici Ospitalieri

    Rome, Italy

  • Ospedale San Eugenio

    Rome, Italy

  • Clinica Ematologica dell'Universita di Roma La Sapienza

    Rome, Italy

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.